Correlation with immunoassay
demonstrates that good correlation exists between MSIA-SRM and immunoassay only when SRM results were averaged across all tryptic peptides. However, when the SRM values from the N-terminal, aa 1-13 tryptic peptide only were considered the correlation was poorer at 0.67. As expected, these results suggest that the immunoassay measures some inactive PTH fragments. Figure 7A illustrates the amino acid sequence for VDBP. Highlighted in red are the tryptic peptide sequences selected for the SRM assay. Figure 7B shows calibration curves for 4 of the peptides, all of which demonstrated similar behavior. Linearity was excellent (R 2 0.95-0.99) with CVs at or above the LOQ < 11 %.
Correlation of VDBP SRM abundance values with Clinical groups
Preliminary work comparing a group of patients with low bone density against controls suggests that low bone density is associated with higher levels of VDBP (mean 234 mg/L) than in patients with CKD (mean 214 mg/ L). Whether such differences alter interpretation of serum total VitD requires further investigation.
A.
Immunoenrichment and quantification using MSIA-SRM (mass spectrometric immunoassay)
In order to develop a sensitive assay with sequence specificity for the PTH and VDBP peptides, we coupled immunoenrichment at the protein level with detection at the peptide level using SRM-MS ( Figure 1 ).
PTH MSIA-SRM development
Peptide selection for PTH assay Following immunoenrichment, the PTH MSIA-SRM approach using four tryptic peptides spanning the length of PTH allows selective detection and quantification of specific isoforms and truncated variants of PTH ( Figure 2 ) . MSIA-SRM Assay Development: Affinity extraction of PTH and VDBP was performed using MSIA pipette tips (absorbed with antibody) on a Versette pipetting robot (Thermo Scientific). Immune-captured material was eluted from the tips and subjected to trypsin digestion followed by liquid chromatography tandem mass spectrometry analysis. This employed a Hypersil Gold column on a TLX2 HPLC system and a TSQ Vantage triple quadrupole mass spectrometer, (both Thermo Scientific) as previously described. SRM assays were developed using Thermo Scientific Pinpoint software. Intact PTH levels were measured using a second generation methodology using an ADVIA Centaur platform (Siemens Healthcare).
PTH bioactivity resides in the intact molecule, PTH(1-84), however, various truncated inactive forms also circulate. Under certain conditions such as renal disease these fragments can accumulate, leading to variable crossreactivity with the PTH immunoassays. To accurately quantify the ratio of intact hormone to its fragments is becoming increasingly significance for the diagnosis of endocrine and osteological diseases. Alongside PTH, vitamin D is also critical in the control of calcium homeostasis. Measurement of serum total vitamin D alone may be misleading because vitamin D and its metabolites circulate tightly bound to vitamin D-binding protein (VDBP), the concentration of which are known to be altered by pregnancy, liver and renal disease and, indeed, genotype. Automated immunoenrichment prior to mass spectrometric analysis forms the basis of Mass Spectrometry Immunoassay (MSIA). Previously, we developed a multiplexed MSIA-single reaction monitoring (SRM) assay for PTH which allows quantification of four fully-tryptic monitoring peptides spanning the entire PTH sequence. Using this approach, it is possible to monitor intact PTH, as well as the degree of N-terminal fragmentation. In this study, the objective was to develop a multiplexed, MSIA-SRM-based targeted assay for VDBP and then apply the MSIA-SRM assays for PTH and VDBP to a cohort of clinical samples. Comparison of MSIA-SRM data for PTH was compared to a commercially available 'intact' PTH immunoassay.
PTH variants in renal disease
Using an SRM corresponding to amino acids 34-44, those with end stage renal failure (ESRF) could be clearly separated from those with CKD stages 2-5, as well as healthy controls ( Figure 5A ). However, when an SRM corresponding to amino acids 35-44 was used, no difference between ESRF, CKD stages 2-5 and controls was observed ( Figure 5B ). Finally, when samples were stratified according to CKD stage and immunoassay PTH result compared to that of the MSIA-SRM intact PTH (N-terminal tryptic peptide), gross overestimate of PTH by immunoassay is demonstrated in those with ESRF (CKD stage 1) ( Figure 6 ).
FIGURE 2. PTH variant map.
B.
PTH heterogeneity in clinical samples
As shown in Table 1 , several PTH variants reported in the literature were detected in our samples. These include N-terminally truncated variants as well as phosphorylated PTH. Surprisingly, we were unable to detect the tryptic peptide corresponding to amino acids 7-13. This is consistent with an absence of PTH(7-84) in our clinical samples, despite this being proposed in the literature as a common PTH variant. A.
B. 
